Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RGEN with free AI briefings, catalyst countdowns, and dilution alerts.

RGEN · REPLIGEN CORP

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$863M Cash on Hand
CF+ Cash Runway
Follow RGEN by email Get an email when RGEN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RGEN, unsubscribe in one click. Privacy

📣 What RGEN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Secretin Human (RG1068) Pancreatitis Phase 3 · NCT00660335 Completed
Uridine Bipolar I Depression Phase 2 · NCT00812058 Completed
Secretin Schizophrenia Phase 2 · NCT00235274 Completed
Uridine Triacetate (RG2133) Mitochondrial Diseases Phase 1 · NCT00060515 Terminated
Secretin Synthetic Human (RG1068) Pancreas Cancer Early Phase 1 · NCT01371240 Withdrawn

Also used in these trials (approved or third-party drugs, not RGEN's own candidates): Abatacept (RG2077).

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RGEN holds $863M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RGEN files for a raise →

👥 Who Owns RGEN

Insiders 0.6% Institutions (723 holders) 99.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 7,361,318 11.52% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 2,825,579 4.42% 2026-06-30
Karen A Dawes
Director · +2,239 options
Insider 92,816 0.15% 2026-05-14
Anthony Hunt
Director
Insider 89,062 0.14% 2026-03-02
Olivier Loeillot
Chief Executive Officer, Director · +48,806 options
Insider 45,788 0.07% 2026-10-05
Glenn P Muir
Director · +4,673 options
Insider 40,051 0.06% 2026-05-14
James Bylund
Chief Operating Officer · +8,315 options
Insider 25,423 0.04% 2026-03-05
Ralf Kuriyel
Senior VP, R&D · +5,669 options
Insider 20,062 0.03% 2026-03-05
Jason K Garland
CFO · +8,315 options
Insider 18,408 0.03% 2026-09-25
Brian Robb Douglass
CHIEF PRODUCT OFFICER · +2,818 options
Insider 8,685 0.01% 2026-10-06
Martin D Madaus
Director · +2,239 options
Insider 8,392 0.01% 2026-05-14
Violetta Hughes
CHIEF ACCOUNTING OFFICER
Insider 6,331 0.01% 2026-03-05

Share count 63,923,738 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RGEN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RGEN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.